Regulatory · source year

2022 regulatory records

42 selected, source-linked regulatory records dated 2022. This is selective source coverage, not a complete timeline.

Dated records

42 selected records.

Peptide profiles

23 connected profiles.

Cited sources

42 distinct public records.

Cited chronology

Dated source records

All record types in 2022 →

December 2022

5 records

November 2022

7 records

Lutetium Lu 177 dotatate

Federal Register notice 2022-25549

The Federal Register published notice 2022-25549, attributed to FDA and its parent HHS department, on 2022-11-23. Its official title is “List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Lutetium Lu 177 dotatate.

Source: Federal Register via GovInfo ↗

→

Calcitonin salmon + 1 more

Federal Register notice 2022-25210

The Federal Register published notice 2022-25210, attributed to FDA and its parent HHS department, on 2022-11-18. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon and Goserelin.

Source: Federal Register via GovInfo ↗

→

October 2022

3 records

September 2022

3 records

Vosoritide

Federal Register notice 2022-19155

The Federal Register published notice 2022-19155, attributed to FDA and its parent HHS department, on 2022-09-06. Its official title is “Issuance of Priority Review Voucher; Rare Pediatric Disease Product,” and PeptideScanner's exact reviewed identity mapping connects the document to Vosoritide.

Source: Federal Register via GovInfo ↗

→

August 2022

8 records

Tirzepatide

Federal Register notice 2022-18523

The Federal Register published notice 2022-18523, attributed to FDA and its parent HHS department, on 2022-08-29. Its official title is “Notice of Approval of Product Under Voucher: Material Threat Medical Countermeasure Priority Review Voucher,” and PeptideScanner's exact reviewed identity mapping connects the document to Tirzepatide.

Source: Federal Register via GovInfo ↗

→

Eptifibatide

Federal Register notice 2022-17056

The Federal Register published notice 2022-17056, attributed to FDA and its parent HHS department, on 2022-08-09. Its official title is “Determination That AVC (Sulfanilamide) Vaginal Cream, 15%, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Eptifibatide.

Source: Federal Register via GovInfo ↗

→

Setmelanotide

Federal Register notice 2022-16502

The Federal Register published notice 2022-16502, attributed to FDA and its parent HHS department, on 2022-08-03. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Setmelanotide.

Source: Federal Register via GovInfo ↗

→

July 2022

3 records

Setmelanotide

Federal Register notice 2022-14134

The Federal Register published notice 2022-14134, attributed to FDA and its parent HHS department, on 2022-07-01. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; IMCIVREE,” and PeptideScanner's exact reviewed identity mapping connects the document to Setmelanotide.

Source: Federal Register via GovInfo ↗

→

June 2022

4 records

May 2022

2 records

Exenatide + 1 more

Federal Register notice 2022-10701

The Federal Register published notice 2022-10701, attributed to FDA and its parent HHS department, on 2022-05-20. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide and Linaclotide.

Source: Federal Register via GovInfo ↗

→

April 2022

3 records

February 2022

2 records

Leuprolide

Federal Register notice 2022-03248

The Federal Register published notice 2022-03248, attributed to FDA and its parent HHS department, on 2022-02-18. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

Source: Federal Register via GovInfo ↗

→

January 2022

2 records

Daptomycin

Federal Register notice 2022-01693

The Federal Register published notice 2022-01693, attributed to FDA and its parent HHS department, on 2022-01-28. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.

Source: Federal Register via GovInfo ↗

→